{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T19:30:05Z","timestamp":1783452605796,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T00:00:00Z","timestamp":1751068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T00:00:00Z","timestamp":1751068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-02866-3","type":"journal-article","created":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T15:19:15Z","timestamp":1751123955000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Regulation of 15-PGDH by ACSM1 in modulating PGE2 signaling and ECM remodeling in prostate cancer"],"prefix":"10.1007","volume":"42","author":[{"given":"Xiaoyu","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongyi","family":"Piao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxi","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changjian","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,28]]},"reference":[{"issue":"2","key":"2866_CR1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10(2):63\u201389.","journal-title":"World J Oncol"},{"issue":"2","key":"2866_CR2","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00345-012-0824-2","volume":"30","author":"OW Brawley","year":"2012","unstructured":"Brawley OW. Prostate cancer epidemiology in the United States. World J Urol. 2012;30(2):195\u2013200.","journal-title":"World J Urol"},{"issue":"9959","key":"2866_CR3","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1016\/S0140-6736(14)60525-0","volume":"384","author":"FH Schroder","year":"2014","unstructured":"Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):2027\u201335.","journal-title":"Lancet"},{"issue":"8","key":"2866_CR4","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/S1470-2045(10)70146-7","volume":"11","author":"J Hugosson","year":"2010","unstructured":"Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010;11(8):725\u201332.","journal-title":"Lancet Oncol"},{"issue":"11","key":"2866_CR5","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1113135","volume":"366","author":"FH Schroder","year":"2012","unstructured":"Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012;366(11):981\u201390.","journal-title":"N Engl J Med"},{"issue":"13","key":"2866_CR6","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","volume":"360","author":"FH Schroder","year":"2009","unstructured":"Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320\u20138.","journal-title":"N Engl J Med"},{"issue":"14","key":"2866_CR7","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1158\/0008-5472.CAN-23-1489","volume":"84","author":"RK Shrestha","year":"2024","unstructured":"Shrestha RK, Nassar ZD, Hanson AR, Iggo R, Townley SL, Dehairs J, et al. ACSM1 and ACSM3 regulate fatty acid metabolism to support prostate cancer growth and constrain ferroptosis. Cancer Res. 2024;84(14):2313\u201332.","journal-title":"Cancer Res"},{"issue":"4","key":"2866_CR8","first-page":"1824","volume":"12","author":"Y Guo","year":"2022","unstructured":"Guo Y, Ren C, Huang W, Yang W, Bao Y. Oncogenic ACSM1 in prostate cancer is through metabolic and extracellular matrix-receptor interaction signaling pathways. Am J Cancer Res. 2022;12(4):1824\u201342.","journal-title":"Am J Cancer Res"},{"issue":"10","key":"2866_CR9","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1038\/s41388-021-01667-y","volume":"40","author":"Y Ma","year":"2021","unstructured":"Ma Y, Zha J, Yang X, Li Q, Zhang Q, Yin A, et al. Long-chain fatty acyl-CoA synthetase 1 promotes prostate cancer progression by elevation of lipogenesis and fatty acid beta-oxidation. Oncogene. 2021;40(10):1806\u201320.","journal-title":"Oncogene"},{"issue":"Pt B","key":"2866_CR10","doi-asserted-by":"publisher","first-page":"108176","DOI":"10.1016\/j.intimp.2021.108176","volume":"101","author":"CC Sun","year":"2021","unstructured":"Sun CC, Zhou ZQ, Yang D, Chen ZL, Zhou YY, Wen W, et al. Recent advances in studies of 15-PGDH as a key enzyme for the degradation of prostaglandins. Int Immunopharmacol. 2021;101(Pt B):108176.","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"2866_CR11","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/10715762.2019.1576867","volume":"53","author":"HO Jang","year":"2019","unstructured":"Jang HO, Lee HN, Woo JH, Lee JY, Kim A, Lee JK, et al. 15-Deoxy-Delta(12,14)-prostaglandin J(2) up-regulates the expression of 15-hydroxyprostaglandin dehydrogenase through DNA methyltransferase 1 inactivation. Free Radic Res. 2019;53(3):335\u201347.","journal-title":"Free Radic Res"},{"issue":"8","key":"2866_CR12","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/s41388-018-0510-y","volume":"38","author":"K Arima","year":"2019","unstructured":"Arima K, Ohmuraya M, Miyake K, Koiwa M, Uchihara T, Izumi D, et al. Inhibition of 15-PGDH causes Kras-driven tumor expansion through prostaglandin E2-ALDH1 signaling in the pancreas. Oncogene. 2019;38(8):1211\u201324.","journal-title":"Oncogene"},{"issue":"6487","key":"2866_CR13","doi-asserted-by":"publisher","first-page":"eaaw5473","DOI":"10.1126\/science.aaw5473","volume":"368","author":"B Faubert","year":"2020","unstructured":"Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science. 2020;368(6487):eaaw5473.","journal-title":"Science"},{"issue":"21","key":"2866_CR14","doi-asserted-by":"publisher","first-page":"35033","DOI":"10.18632\/oncotarget.16591","volume":"8","author":"LM Mehdawi","year":"2017","unstructured":"Mehdawi LM, Satapathy SR, Gustafsson A, Lundholm K, Alvarado-Kristensson M, Sjolander A. A potential anti-tumor effect of leukotriene C4 through the induction of 15-hydroxyprostaglandin dehydrogenase expression in colon cancer cells. Oncotarget. 2017;8(21):35033\u201347.","journal-title":"Oncotarget"},{"issue":"4","key":"2866_CR15","doi-asserted-by":"publisher","first-page":"e0176106","DOI":"10.1371\/journal.pone.0176106","volume":"12","author":"L Yao","year":"2017","unstructured":"Yao L, Chen W, Song K, Han C, Gandhi CR, Lim K, et al. 15-hydroxyprostaglandin dehydrogenase (15-PGDH) prevents lipopolysaccharide (LPS)-induced acute liver injury. PLoS ONE. 2017;12(4):e0176106.","journal-title":"PLoS ONE"},{"issue":"6","key":"2866_CR16","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1074\/jbc.M506846200","volume":"281","author":"S Pavlovic","year":"2006","unstructured":"Pavlovic S, Du B, Sakamoto K, Khan KM, Natarajan C, Breyer RM, et al. Targeting prostaglandin E2 receptors as an alternative strategy to block cyclooxygenase-2-dependent extracellular matrix-induced matrix metalloproteinase-9 expression by macrophages. J Biol Chem. 2006;281(6):3321\u20138.","journal-title":"J Biol Chem"},{"issue":"8","key":"2866_CR17","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.tcb.2014.06.001","volume":"24","author":"D Ackerman","year":"2014","unstructured":"Ackerman D, Simon MC. Hypoxia, lipids, and cancer: surviving the harsh tumor microenvironment. Trends Cell Biol. 2014;24(8):472\u20138.","journal-title":"Trends Cell Biol"},{"issue":"5","key":"2866_CR18","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1210\/en.2012-2074","volume":"154","author":"BT Vo","year":"2013","unstructured":"Vo BT, Morton D Jr, Komaragiri S, Millena AC, Leath C, Khan SA. TGF-beta effects on prostate cancer cell migration and invasion are mediated by PGE2 through activation of PI3K\/AKT\/mTOR pathway. Endocrinology. 2013;154(5):1768\u201379.","journal-title":"Endocrinology"},{"issue":"5","key":"2866_CR19","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1074\/jbc.M411221200","volume":"280","author":"MG Backlund","year":"2005","unstructured":"Backlund MG, Mann JR, Holla VR, Buchanan FG, Tai HH, Musiek ES, et al. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem. 2005;280(5):3217\u201323.","journal-title":"J Biol Chem"},{"issue":"10","key":"2866_CR20","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1074\/mcp.R800011-MCP200","volume":"7","author":"JE Celis","year":"2008","unstructured":"Celis JE, Gromov P, Cabezon T, Moreira JM, Friis E, Jirstrom K, et al. 15-prostaglandin dehydrogenase expression alone or in combination with ACSM1 defines a subgroup of the apocrine molecular subtype of breast carcinoma. Mol Cell Proteomics MCP. 2008;7(10):1795\u2013809.","journal-title":"Mol Cell Proteomics MCP"},{"issue":"1","key":"2866_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13062-024-00591-x","volume":"20","author":"G Cong","year":"2025","unstructured":"Cong G, Shao J, Xiao F, Zhu H, Kang P. The role of endothelial cell-related gene COL1A1 in prostate cancer diagnosis and immunotherapy: insights from machine learning and single-cell analysis. Biol Direct. 2025;20(1):3.","journal-title":"Biol Direct"},{"issue":"2","key":"2866_CR22","doi-asserted-by":"publisher","first-page":"e2100096","DOI":"10.1002\/adma.202100096","volume":"34","author":"MJ Mosquera","year":"2022","unstructured":"Mosquera MJ, Kim S, Bareja R, Fang Z, Cai S, Pan H, et al. Extracellular matrix in synthetic hydrogel-based prostate cancer organoids regulate therapeutic response to EZH2 and DRD2 inhibitors. Adv Mater. 2022;34(2):e2100096.","journal-title":"Adv Mater"},{"key":"2866_CR23","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3389\/fmolb.2019.00160","volume":"6","author":"E Henke","year":"2019","unstructured":"Henke E, Nandigama R, Ergun S. Extracellular matrix in the tumor microenvironment and its impact on cancer therapy. Front Mol Biosci. 2019;6:160.","journal-title":"Front Mol Biosci"},{"issue":"11","key":"2866_CR24","doi-asserted-by":"publisher","first-page":"5385","DOI":"10.21873\/anticanres.16043","volume":"42","author":"SH Kim","year":"2022","unstructured":"Kim SH, Song SE, Baik H, Hur DY, Kang MS, Bae KB. 15-Prostaglandin dehydrogenase inhibition enhances colon cancer metastasis by up-regulation of epithelial-to-mesenchymal transition genes. Anticancer Res. 2022;42(11):5385\u201396.","journal-title":"Anticancer Res"},{"issue":"7757","key":"2866_CR25","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","volume":"569","author":"M Ghandi","year":"2019","unstructured":"Ghandi M, Huang FW, Jane-Valbuena J, Kryukov GV, Lo CC, McDonald ER 3rd, et al. Next-generation characterization of the cancer cell line encyclopedia. Nature. 2019;569(7757):503\u20138.","journal-title":"Nature"},{"issue":"9","key":"2866_CR26","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.3390\/ijms22094297","volume":"22","author":"MT Ferreira","year":"2021","unstructured":"Ferreira MT, Miyake JA, Gomes RN, Feitoza F, Stevannato PB, da Cunha AS, et al. Cyclooxygenase inhibition alters proliferative, migratory, and invasive properties of human glioblastoma cells in vitro. Int J Mol Sci. 2021;22(9):4297.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2866_CR27","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1124\/jpet.112.200444","volume":"344","author":"J Jiang","year":"2013","unstructured":"Jiang J, Dingledine R. Role of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation. J Pharmacol Exp Ther. 2013;344(2):360\u20137.","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02866-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02866-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02866-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T00:01:11Z","timestamp":1757203271000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02866-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,28]]},"references-count":27,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["2866"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02866-3","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,28]]},"assertion":[{"value":"29 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not involve.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of Ethics"}}],"article-number":"297"}}